When used as a primary prophylaxis, biosimilar filgrastim (Zarxio) was found to be cost-effective when used to treat patients with nonmetastatic non–small cell lung cancer (NSCLC), according to a study presented at ASCO20 Virtual, the annual meeting of the American Society of Clinical Oncology (ASCO).
For patients with nonmetastatic non—small cell lung cancer (NSCLC) who are at intermediate-risk of developing febrile neutropenia (FN), biosimilar filgrastim (Zarxio) is cost-effective when used as a primary prophylaxis (PP) when a payer’s willingness-to-pay (WTP) threshold is $50,000 per quality-adjusted life-year (QALY) gained, according to a new study.
Findings were presented at ASCO20 Virtual, the annual meeting of the American Society of Clinical Oncology. Patients with nonmetastatic NSCLC are at intermediate risk (10%-20%) of developing FN if they are receiving platinum-based chemotherapy.
Authors said most patients with NSCLC who receive chemotherapy have ≥1 FN risk factors, and although PP can reduce the incidence of FN, it is more costly than secondary prophylaxis (SP).
The study used a Markov statistical model to evaluate PP versus SP to prevent chemotherapy-induced FN in patients 61 years of age receiving adjuvant carboplatin/paclitaxel every 3 weeks for 4 cycles.
Investigators conducted separate analyses for patients with 0 FN risk factors and ≥1 FN risk factors, representing 11.3% and 18% baseline FN risk, respectively. They calculated incremental cost-effectiveness ratios (ICERs) for cost per FN event avoided, life-year saved (LYS), and QALY gained from a United States payer perspective.
Cost-Effectiveness for Patients
Use of filgrastim as PP versus SP provided an additional 0.056 QALYs (0.079 LYS) for patients with 0 risk factors, at an incremental cost of $3266. For cost per FN event avoided, cost per LYS, and cost per QALY gained, the ICERs were $46,815, $41,555, and $58,531, respectively.
For patients with 1 or more risk factors for FN, PP versus SP added 0.090 QALYs (0.127 LYS) at an incremental cost of $1605. For cost per FN event avoided, cost per LYS, and cost per QALY gained, the ICERs were $13,970, $12,644, and $17,805, respectively.
Investigators also conducted deterministic and probabilistic sensitivity analyses, finding that the likelihood of cost-effectiveness at a WTP threshold of $50,000 per QALY gained was 31.7% for patients with 0 risk factors for FN and 96.6% for those with at least 1 FN risk factor.
Reference
Li EC, Mezzio D, Spargo K, Campbell KJ, Lyman GH. Cost-effectiveness of filgrastim-sndz as primary prophylaxis (PP) versus secondary prophylaxis (SP) to prevent chemotherapy-induced febrile neutropenia (FN) in non-small cell lung cancer (NSCLC) patients at intermediate risk. Presented at ASCO20 Virtual; May 30-31, 2020. Abstract e19401
Cencora Analysis Shows Differences in Payer Coverage Between G-CSF Biosimilars
May 2nd 2024Data from a Cencora study showed some misalignment in payer coverage of granulocyte colony-stimulating factor (G-CSF) biosimilars, highlighting that while filgrastim biosimilars are often favored over the originator, reference pegfilgrastim still dominates over its biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
AON Saves Over $243 Million With High Biosimilar Adoption
April 22nd 2024Thanks to high biosimilar adoption rates within the community oncology setting, American Oncology Network (AON) saved upwards of $243 million between 2020 and 2023, according to a presentation at the Festival of Biologics USA conference in San Diego, California.
The 6 Key Policy Factors to Ensure Biosimilar Market Sustainability
April 16th 2024Magnus Bodin, senior director and head of international access and policy at Biogen, presented warning signs for unsustainable biosimilar markets as well as key factors needed to create effective policies and future-proof biosimilar markets globally.